FDA approves at-home use of BioXcel's agitation drug IgalmiThe FDA approved at-home use of BioXcel Therapeutics' Igalmi (dexmedetomidine) for agitation associated with schizophrenia or bipolar disorder, expanding access beyond clinical settings.Nov 16, 2026·2 sourcesFDA drug approvalMental Health & WellbeingDrug Policy, Pricing & ApprovalPsychosis & schizophrenia spectrum00